← Russell 3000 cross-section

SMTI Sanara MedTech Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$319m
Revenue TTM
$110m
Net income TTM
$-32m
Free cash flow
$4m
Composite score
53.3
Sector rank
#2623

Valuation

P / E
EV / EBITDA
20.9
EV / sales
3.2
FCF yield
1.41%
Earnings yield vs 10-yr
-14.75pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-29.2%
EBITDA margin
15.3%
ROE
-403.0%
ROIC
35.5%
Revenue growth
12.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

COMPONENTS OF RESULTS OF OPERATIONS Sources of Revenue Our revenue is derived primarily from sales of our soft tissue repair and bone fusion products to hospitals and surgical centers. Our revenue is driven by direct orders shipped by us to our customers, and, to a lesser extent, direct sales to customers through delivery at the time of procedure by one of our sales representatives. Revenue streams from product sales are summarized below for the periods presented: Cost of Goods Sold Cost of goods sold consists primarily of finished goods purchases, raw material costs for certain components sourced directly by us, shipping and handling and all related royalties due as a result of the sale of …Sanara MedTech Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →